+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Transfection Technologies Market Report and Forecast 2023-2031

  • PDF Icon


  • 140 Pages
  • July 2023
  • Region: Global
  • Expert Market Research
  • ID: 5855101
The global transfection technologies market attained a value of USD 1048.5 million in 2022, driven by increasing demand for genetic research, biotechnology applications, and gene therapy approaches. The market is expected to grow at a CAGR of 8.5% during the forecast period of 2023-2031 to attain a value of USD 2184.3 million by 2031.

Transfection Technologies: Introduction

Transfection technologies refer to a set of techniques used to introduce genetic material, such as DNA or RNA, into cells. These techniques enable the delivery of foreign genetic material into cells, allowing researchers to manipulate gene expression, study gene function, and explore various cellular processes. Transfection technologies offer several uses and benefits in biological research and biotechnology.

The benefits of transfection technologies include:

  • Versatility: Transfection methods offer a versatile approach for delivering genetic material into a wide range of cell types, including primary cells, immortalized cell lines, and even in vivo systems. This versatility enables researchers to study various biological processes and disease models across different cell types and organisms
  • Precise Manipulation: Transfection techniques allow researchers to precisely manipulate gene expression, enabling the investigation of specific genes and their roles in cellular processes. This provides valuable insights into gene function, cellular pathways, and disease mechanisms
  • Customizability: Transfection technologies can be tailored to specific research needs. Researchers can choose different transfection methods, such as lipid-based transfection, electroporation, or viral transduction, based on the target cell type, desired gene expression duration, and other experimental requirements
  • Efficiency and Reproducibility: With advancements in transfection technologies, the efficiency of delivering genetic material into cells has significantly improved. High transfection efficiency and reproducibility are crucial for obtaining consistent and reliable experimental results
  • Therapeutic Applications: Transfection techniques have paved the way for gene therapy and the development of novel therapeutic strategies. By delivering therapeutic genes or RNA molecules into cells, transfection technologies hold promises for treating genetic disorders, cancer, and other diseases
It is important to note that transfection techniques should be carefully optimized and validated for specific cell types and experimental conditions to ensure successful delivery and minimize cellular stress or toxicity.

Transfection Technologies Market Segmentations

The market can be categorised into method, application, products, end user, and region.

Market Breakup by Method

  • Reagent-based Method
  • Instrument-based Method
  • Other Methods

Market Breakup by Application

  • Biomedical Research
  • Therapeutic Delivery
  • Protein Production

Market Breakup by Products

  • Reagent
  • Instrument
  • Others

Market Breakup by End User

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic and Research Institutes
Transfection Technologies Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Transfection Technologies Market Overview

The transfection technologies market has witnessed substantial growth and is expected to continue expanding in the coming years. Several factors contribute to the positive market scenario.

One of the primary drivers of market growth is the increasing demand for genetic research and biotechnology applications. The advancements in genomics, proteomics, and personalized medicine have created a growing need for efficient and reliable transfection technologies. Researchers and biotechnology companies rely on these techniques to introduce foreign genetic material into cells for studying gene function, protein expression, disease modelling, and therapeutic development.

Moreover, the rise in genetic engineering and gene therapy approaches has fuelled market demand for transfection technologies. With the increasing interest in modifying gene expression, manipulating cellular processes, and developing targeted therapies, transfection techniques play a crucial role in delivering therapeutic genes, RNA molecules, or genome-editing tools into target cells. The potential of transfection technologies to enable precise and controlled genetic manipulation has attracted significant attention and investment in the field.

Furthermore, technological advancements have contributed to market growth. The development of innovative transfection reagents, viral vectors, and delivery systems has improved the efficiency, safety, and ease of use of transfection technologies. These advancements have expanded the range of transfection applications and facilitated the delivery of genetic material into various cell types, including primary cells, stem cells, and hard-to-transfect cell lines.

Key players in the global transfection technologies market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the transfection technologies market are as follows:
  • Lonza Group
  • Bio-Rad Laboratories, Inc
  • Thermo Fisher Scientific
  • Qiagen NV
  • Promega Corporation
  • SignaGen Laboratories
  • Merck KGaA
  • Altogen Biosystems
  • Polyplus-transfection SA
  • Mirus Bio
*The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Transfection Technologies Market Overview
3.1 Transfection Technologies Market Historical Value (2016-2022)
3.2 Transfection Technologies Market Forecast Value (2023-2031)
4 Transfection Technologies Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Transfection Technologies Market Segmentation
5.1 Transfection Technologies Market by Type
5.1.1 Market Overview
5.1.2 Reagent-based Method
5.1.3 Instrument-based Method
5.1.4 Others
5.2 Transfection Technologies Market by Applications
5.2.1 Market Overview
5.2.2 Biomedical Research
5.2.3 Therapeutic Delivery
5.2.4 Protein Production
5.3 Transfection Technologies Market by Region
5.3.1 Market Overview
5.3.2 North America
5.3.3 Europe
5.3.4 Asia Pacific
5.3.5 Latin America
5.3.6 Middle East and Africa
6 North America Transfection Technologies Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Transfection Technologies Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Transfection Technologies Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.6 Australia
8.7 Others
9 Latin America Transfection Technologies Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Transfection Technologies Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Regulatory Framework
11.1 Regulatory Overview
11.1.1 US FDA
11.1.2 EU EMA
11.1.5 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Lonza Group
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Bio-Rad Laboratories, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Thermo Fisher Scientific
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Qiagen NV
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Promega Corporation
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 SignaGen Laboratories
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Merck KGaA
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Altogen Biosystems
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Polyplus-transfection SA
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Mirus Bio
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
  • *Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Lonza Group
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific
  • Qiagen NV
  • Promega Corporation
  • SignaGen Laboratories
  • Merck KGaA
  • Altogen Biosystems
  • Polyplus-transfection SA
  • Mirus Bio



Table Information